| 1663 |
1471: Increase, Uncoupling of photophosphorylation |
1472: Decrease, ATP production |
Oct 10, 2017 |
Oct 10, 2017 |
1 AOP
|
| 795 |
793: Increase, Urinary bladder calculi |
794: Increase, Cytotoxicity (urothelial cells) |
Nov 29, 2016 |
Dec 3, 2016 |
1 AOP
|
| 3018 |
2161: Increase, Vascular disrupting effects |
2160: Angiogenesis disfunction |
Aug 21, 2023 |
Aug 21, 2023 |
None
|
| 1444 |
1342: Increase, vascular smooth muscle contraction |
1343: Increase, hypertension |
Apr 14, 2017 |
Apr 14, 2017 |
2 AOPs
|
| 2738 |
2046: Increase, Vitellogenin mRNA |
2047: Delay, Ovarian maturation |
Aug 28, 2022 |
Aug 28, 2022 |
1 AOP
|
| 336 |
307: Increase, Vitellogenin synthesis in liver |
220: Increase, Plasma vitellogenin concentrations |
Nov 29, 2016 |
Jun 24, 2024 |
3 AOPs
|
| 2068 |
1745: Increase,collagen synthesis |
1746: Induction lung fibrosis |
Mar 17, 2020 |
Mar 17, 2020 |
None
|
| 2527 |
1888: increased atRA concentration |
1889: premature meiosis, male germ cells |
Nov 10, 2021 |
Nov 11, 2021 |
1 AOP
|
| 2509 |
1948: Upregulation of ACE2 |
1738: SARS-CoV-2 cell entry |
Oct 28, 2021 |
Oct 28, 2021 |
None
|
| 1238 |
1172: Increased activation, Nuclear factor kappa B (NF-kB) |
1170: Increase, Phenotypic enzyme activity |
Nov 29, 2016 |
Dec 3, 2016 |
None
|
| 2309 |
1172: Increased activation, Nuclear factor kappa B (NF-kB) |
1496: Increased proinflammatory mediators |
Mar 30, 2021 |
Mar 30, 2021 |
3 AOPs
|
| 2431 |
1172: Increased activation, Nuclear factor kappa B (NF-kB) |
87: Release, Cytokine |
Jul 8, 2021 |
Jul 8, 2021 |
1 AOP
|
| 2432 |
1172: Increased activation, Nuclear factor kappa B (NF-kB) |
1493: Increased pro-inflammatory mediators |
Jul 8, 2021 |
Jul 8, 2021 |
1 AOP
|
| 2612 |
1172: Increased activation, Nuclear factor kappa B (NF-kB) |
112: Antagonism, Estrogen receptor |
Mar 22, 2022 |
Aug 27, 2023 |
1 AOP
|
| 1080 |
1039: Increased activity, beta-2 adrenergic receptor |
1040: relaxation, smooth muscle |
Nov 29, 2016 |
Dec 3, 2016 |
1 AOP
|
| 2898 |
2128: Increased adipocyte numbers |
2125: Increased fat mass |
May 4, 2023 |
May 4, 2023 |
1 AOP
|
| 2899 |
2127: Increased adipocyte size |
2125: Increased fat mass |
May 4, 2023 |
May 4, 2023 |
1 AOP
|
| 1612 |
1449: increased adipogenesis |
1447: obesity |
Jul 24, 2017 |
Jul 24, 2017 |
1 AOP
|
| 2323 |
1852: Increased Ang II type 1 receptor (AT1R) |
1115: Increase, ROS |
Apr 10, 2021 |
Apr 10, 2021 |
2 AOPs
|
| 2066 |
1752: Increased AngII |
1743: Increase plasma Ang II |
Mar 17, 2020 |
Mar 17, 2020 |
None
|
| 2298 |
1752: Increased AngII |
1849: Impaired gustatory nerve |
Mar 28, 2021 |
Mar 28, 2021 |
None
|
| 2300 |
1752: Increased AngII |
1496: Increased proinflammatory mediators |
Mar 28, 2021 |
Mar 28, 2021 |
None
|
| 2317 |
1752: Increased AngII |
1856: Sodium inhibition, Sweet enhancement |
Apr 10, 2021 |
Apr 10, 2021 |
1 AOP
|
| 2327 |
1752: Increased AngII |
1852: Increased Ang II type 1 receptor (AT1R) |
Apr 10, 2021 |
Apr 10, 2021 |
1 AOP
|
| 2593 |
1752: Increased AngII |
1851: Binding of agonist, Angiotensin II receptor type 1 receptor (AT1R) |
Mar 3, 2022 |
Mar 3, 2022 |
1 AOP
|